These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 11600351)

  • 21. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
    Ghosh AK; Chapsal BD; Weber IT; Mitsuya H
    Acc Chem Res; 2008 Jan; 41(1):78-86. PubMed ID: 17722874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of the nelfinavir resistance-conferring mutation D30N on the susceptibility of HIV-1 subtype B to other protease inhibitors.
    Santos AF; Soares MA
    Mem Inst Oswaldo Cruz; 2011 Mar; 106(2):177-81. PubMed ID: 21537677
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
    Corbett JW; Ko SS; Rodgers JD; Gearhart LA; Magnus NA; Bacheler LT; Diamond S; Jeffrey S; Klabe RM; Cordova BC; Garber S; Logue K; Trainor GL; Anderson PS; Erickson-Viitanen SK
    J Med Chem; 2000 May; 43(10):2019-30. PubMed ID: 10821714
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV-1 proteases from drug-naive West African patients are differentially less susceptible to protease inhibitors.
    Kinomoto M; Appiah-Opong R; Brandful JA; Yokoyama M; Nii-Trebi N; Ugly-Kwame E; Sato H; Ofori-Adjei D; Kurata T; Barre-Sinoussi F; Sata T; Tokunaga K
    Clin Infect Dis; 2005 Jul; 41(2):243-51. PubMed ID: 15983923
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors.
    Gatanaga H; Suzuki Y; Tsang H; Yoshimura K; Kavlick MF; Nagashima K; Gorelick RJ; Mardy S; Tang C; Summers MF; Mitsuya H
    J Biol Chem; 2002 Feb; 277(8):5952-61. PubMed ID: 11741936
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monitoring resistance to human immunodeficiency virus type 1 protease inhibitors by pyrosequencing.
    O'Meara D; Wilbe K; Leitner T; Hejdeman B; Albert J; Lundeberg J
    J Clin Microbiol; 2001 Feb; 39(2):464-73. PubMed ID: 11158091
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy.
    Condra JH; Petropoulos CJ; Ziermann R; Schleif WA; Shivaprakash M; Emini EA
    J Infect Dis; 2000 Sep; 182(3):758-65. PubMed ID: 10950769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients.
    Torti C; Quiros-Roldan E; Monno L; Patroni A; Saracino A; Angarano G; Tinelli C; Lo Caputo S; Tirelli V; Mazzotta F; Carosi G; ;
    J Med Virol; 2004 Sep; 74(1):29-33. PubMed ID: 15258965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical pharmacology and pharmacokinetics of amprenavir.
    Sadler BM; Stein DS
    Ann Pharmacother; 2002 Jan; 36(1):102-18. PubMed ID: 11816239
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human immunodeficiency virus type 1 hypersusceptibility to amprenavir in vitro can be associated with virus load response to treatment in vivo.
    Zachary KC; Hanna GJ; D'Aquila RT
    Clin Infect Dis; 2001 Dec; 33(12):2075-7. PubMed ID: 11700580
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of increasing alpha1-acid glycoprotein concentration on the antiviral efficacy of human immunodeficiency virus protease inhibitors.
    Zhang XQ; Schooley RT; Gerber JG
    J Infect Dis; 1999 Dec; 180(6):1833-7. PubMed ID: 10558938
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phenotypic HIV-1 resistance correlates with treatment outcome of nelfinavir salvage therapy.
    Walter H; Schmidt B; Rascu A; Helm M; Moschik B; Paatz C; Kurowski M; Korn K; Uberla K; Harrer T
    Antivir Ther; 2000 Dec; 5(4):249-56. PubMed ID: 11142619
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV.
    Hazen R; Harvey R; Ferris R; Craig C; Yates P; Griffin P; Miller J; Kaldor I; Ray J; Samano V; Furfine E; Spaltenstein A; Hale M; Tung R; St Clair M; Hanlon M; Boone L
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3147-54. PubMed ID: 17620375
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amprenavir may be less cross-resistant with other PIs.
    Murphy MJ
    HIV Clin; 1999; 11(5):1, 7. PubMed ID: 11810849
    [No Abstract]   [Full Text] [Related]  

  • 36. Genotypic and phenotypic evolution of HIV type-1 protease during in vitro sequential or concomitant combination of atazanavir and amprenavir.
    Cunyat F; Ruiz L; Marfil S; Puig T; Bofill M; Blanco J; Clotet B; Cabrera C
    Antivir Ther; 2010; 15(3):431-6. PubMed ID: 20516562
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients.
    Turner D; Schapiro JM; Brenner BG; Wainberg MA
    Antivir Ther; 2004 Jun; 9(3):301-14. PubMed ID: 15259893
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors.
    Poveda E; de Mendoza C; Martin-Carbonero L; Corral A; Briz V; González-Lahoz J; Soriano V
    J Antimicrob Chemother; 2007 Oct; 60(4):885-8. PubMed ID: 17646201
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of polymorphisms at position 89 in the HIV-1 protease gene in the development of drug resistance to HIV-1 protease inhibitors.
    Martinez-Cajas JL; Wainberg MA; Oliveira M; Asahchop EL; Doualla-Bell F; Lisovsky I; Moisi D; Mendelson E; Grossman Z; Brenner BG
    J Antimicrob Chemother; 2012 Apr; 67(4):988-94. PubMed ID: 22315096
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia.
    Paulsen D; Liao Q; Fusco G; St Clair M; Shaefer M; Ross L
    AIDS Res Hum Retroviruses; 2002 Sep; 18(14):1011-9. PubMed ID: 12396453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.